epaminurad

Epaminurad is an investigational small molecule drug developed by JW Pharmaceutical for the treatment of gout and hyperuricemia. It acts as a selective inhibitor of the human uric acid transporter 1 (URAT1/SLC22A12), promoting urate excretion by blocking renal reabsorption of uric acid. This mechanism lowers serum urate levels and addresses both acute symptoms and the underlying cause of hyperuricemia in gout patients. As of 2025, epaminurad is in Phase 3 clinical trials comparing its efficacy to febuxostat in patients with gout across multiple Asian countries[1][2][5][6].

Other names

epaminurad [INN](3,5-dibromo-4-hydroxyphenyl)(2,3-dihydro-4H-pyrido(4,3-b)-1,4-oxazin-4-yl)methanoneMethanone, (3,5-dibromo-4-hydroxyphenyl)(2,3-dihydro-4H-pyrido(4,3-b)-1,4 oxazin 4 yl)-